Another study on k-ras mutated colorectal cancer cells using genome-wide CRISPR/Cas9 screens technology identified the role of the Wnt/B-catenin signaling pathway in resistance to BCL-XL inhibitor ABT-263. This evidence concerns the gene KRAS and colorectal cancer.